MDL 62208, MDL 62211, and MDL 62873 are three semisynthetic amide derivatives of teicoplanin (MDL 62208 is an amide of teicoplanin aglycone, MDL 62211 is an amide of the teicoplanmn A2 complex, and MDL 62873 is the corresponding derivative of peak A2-2 of the complex). The three semisynthetic glycopeptides were evaluated for in vitro antibacterial activity in comparison with the parent drug (teicoplanin) and vancomycin.
Vancomycin, the first glycopeptide antibiotic, was introduced into clinical practice in the late 1950s essentially to deal with those serious infections caused by penicillinaseproducing strains of Staphylococcus aureus, which were raging out of control at that time. Even though highly effective in the treatment of such infections, the drug soon lost favor because of its toxicity (especially oto-and nephrotoxicities) and adverse reactions during administration (44) and was quickly overshadowed by the new drugs methicillin and cephalothin. Unlike ristocetin (another glycopeptide antibiotic which proved to be toxic to bone marrow and to cause platelet aggregation and was thus soon withdrawn [28] ), vancotnycin, although virtually unused for many years, was nevertheless kept on the market.
A renewal of interest in vancomycin began in the late 1970s. This new trend arose for a variety of concurrent reasons, including (i) the progressive increase in infections caused by gram-positive bacteria, after 2 decades during which the proportion of such infections had substantially dropped under pressure from gram-negative organisms; (ii) the emergence, especially in hospital-associated infections of compromised patients, of highly and often multiply resistant but vancomycin-susceptible, gram-positive pathogens (e.g., methicillin-resistant staphylococci, enterococci, or JK corynebacteria); (iii) the proposal of new uses for vancomycin, such as its oral administration as a topical agent in the treatment of pseudomembranous colitis or its use in prophylactic regimens; and (iv) the improved control of vancomycin toxicity resulting from both the greater purity of modem drug formulations and the clinical monitoring of levels in serum.
The same factors leading to the revival of vancomycin * Corresponding author. 331 prompted research programs in the pharmaceutical industry aimed at developing new glycopeptide antibiotics. Teicoplanin, which became commercially available in Europe in the late 1980s, demonstrated greater activity than vancomycin in vitro (25, 27, 37) and favorable pharmacokinetics (43) associated with ease of administration and safety in clinical practice (41) . New glycopeptides, including both natural (12, 31) and semisynthetic (18, 22, 26, 34) molecules, are currently being investigated for future development. In particular, a large number of compounds resulting from the condensation of the carboxyl group of teicoplanin with amines carrying various functional groups and chains have been synthesized and investigated for structure-activity relationships (22) .
In this study, we (38) , streptococci and enterococci (9) , listeriae (30) , coryneform bacteria (20) , and anaerobic gram-positive organisms (14) . The 16 ,ug/ml; resistant, -32 ,ug/ml. Teicoplanin is not reported in the latest documents published by the National Committee for Clinical Laboratory Standards, but this same committee has very recently approved the following breakpoints for this drug (11, 17) : susceptible, <8 ,ug/ml; intermediate, 16 ,ug/ml; resistant, .32 ,ug/ml. We tentatively applied these same MIC breakpoints to the teicoplanin derivatives as well, considering their close structural relationship to teicoplanin.
Assessment of bactericidal activity. MBCs were established by extending the MIC procedure to the evaluation of bactericidal activity. This approach was applied not only to aerobic organisms, but, because of a lack of standardized alternatives, also tentatively to anaerobic bacteria. After the MIC was read, 0.025-ml volumes were drawn with an Eppendorf pipette from the wells showing no growth and were spread onto suitable agar plates (over at least a quarter of the surface to avoid drug carryover effects). These plates were incubated (aerobically or anaerobically, depending on the organisms) at 35°C for 24 to 48 h. The MBC was read as the lowest concentration of antibiotic which resulted in 'O0.1% survival in the subculture. Table 2 (streptococci, enterococci, listeriae, and group JK corynebacteria), and Table 3 (anaerobic gram-positive bacteria). The results obtained with those isolates which were found to be resistant or intermediate to at least one of the five glycopeptide antibiotics examined are detailed in Table 4 .
RESULTS
The three semisynthetic derivatives of teicoplanin were highly active against both methicillin-susceptible and methicillin-resistant staphylococci. This was also true for those coagulase-negative isolates (15 of S. haemolyticus and 2 of S. epidermidis, all methicillin resistant except one methicillin-susceptible isolate in each species) which proved to be resistant to teicoplanin. The MICs of MDL 62208 did not usually exceed 0.5 ,ugIml, a value of 1 ,g/ml being recorded 332 BIAVASCO ET AL.
on September 7, 2017 by guest http://aac.asm.org/ Staphylococcus haemolyticus, methicillin susceptible (10) Staphylococcus haemolyticus, methicillin resistant (29) Staphylococcus simulansb (20) Staphylococcus saprophyticusc (18) Staphylococcus hominisd (14) Other Staphylococcus spp.e (23) (Table 4) . For streptococci, the MICs of the teicoplanin derivatives were generally lower than for staphylococci and mostly overlapped with the MICs of teicoplanin. Vancomycin MICs were 2-to 16-fold higher.
The MICs of the three teicoplanin derivatives for the 77 randomly collected enterococci never exceeded 0.25 ,ug/ml and were generally identical to or 2-fold lower (but occasionally up to 16-fold lower) than the MICs of teicoplanin. Vancomycin MICs were 4-to 32-fold higher. Since we did not find any MBCs exceeded MICs to a variable extent, depending on the particular glycopeptide but especially on the organisms (Table 5) . Overall, the MBC-to-MIC ratios yielded by the teicoplanin derivatives were slightly greater than those yielded by teicoplanin or vancomycin. With all antimicrobial agents, the highest MBC-to-MIC ratios were observed for enterococci, with values of 216 recorded for most isolates, and for L. monocytogenes, with values distributed over a wide range but being 216 for over half of the strains. Ratios were mostly in the range 1 to 2 for streptococci, and 2 to 4 for JK coryneform bacteria and anaerobic bacteria. For the majority of Staphylococcus isolates, the MBC-to-MIC ratios fell in the range 1 to 4 with the teicoplanin amides and 1 to 2 with teicoplanin and vancomycin, with no significant differences between either S. aureus and coagulase-negative staphylococci or methicillin-susceptible and methicillin-resistant isolates.
DISCUSSION
Glycopeptide antibiotics are active against a wide range of gram-positive bacteria, including those genera which are most commonly involved in human infections. Other grampositive genera such as Leuconostoc, Pediococcus, Lactobacillus, and Erysipelothrix, all rare or uncertain human pathogens, seem inherently resistant to glycopeptides (16) . Among those organisms within the spectrum of activity, there has been no trend towards vancomycin resistance during 30 years of clinical experience with this antibiotic (5) , and a similar uniform susceptibility was apparently also the rule with teicoplanin (25, 27, 37) . In order to explain this unique nonemergence of in vitro resistances, it was even hypothesized that mutations which would lead to a change in the D-alanyl-D-alanine target and so reduce glycopeptide binding would also affect the synthesis of a rigid peptidoglycan and hence be lethal for the cell (29) .
During the last few years, however, strains resistant to vancomycin or teicoplanin or both have emerged among staphylococci and enterococci. Within staphylococci, resistant strains, usually more resistant to teicoplanin than to vancomycin, are largely confined to S. haemolyticus (1, 7, 33, 39, 42) (3, 32, 40) . In recent French studies (8, 13) , resistant strains have also been reported among S. epidermidis clinical isolates, and this finding is confirmed by the present study. Within enterococci, after initial reports of resistances (19, 21, 36) , two major phenotypes of resistant strains have been described: one is characterized by inducible, high-level resistance to both vancomycin and teicoplanin, and one is characterized by lower-level resistance to vancomycin and susceptibility to teicoplanin (6, 35 (25) .
Although having expectedly high MBC-to-MIC ratios (as for teicoplanin and vancomycin or even greater), the experimental glycopeptides were very active against all randomly collected enterococci, with MICs similar to or slightly lower than those of teicoplanin and considerably lower than those of vancomycin. However, the three teicoplanin derivatives were substantially devoid of activity against the five selected strains already known to be highly resistant to both vancomycin and teicoplanin, with MICs even higher than those of the parent drug. These were the only resistances to the teicoplanin derivatives we observed in this study. It is worth noting that when a few enterococci highly resistant to vancomycin and teicoplanin were tested for susceptibility to a number of experimental derivatives of vancomycin, they were reported to be cross-resistant to some such compounds but susceptible to others (26) . In the present study, we did not have the opportunity to test any strain of another enterococcal phenotype which is reported to be resistant to lower levels of vancomycin and to remain susceptible to teicoplanin (6, 35) . However, for an enterococcus of this phenotype (vancomycin MIC, 32 ,ug/ml; teicoplanin MIC, 0.5 ,ug/ml), Shlaes et 
